Nuvation Bio, Inc. (NUVB)
6.81
+0.04
(+0.59%)
USD |
NYSE |
Sep 04, 16:00
6.82
+0.01
(+0.15%)
After-Hours: 20:00
Nuvation Bio Research and Development Expense (Quarterly) : 30.66M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.66M |
| March 31, 2026 | 35.05M |
| December 31, 2025 | 34.30M |
| September 30, 2025 | 28.85M |
| June 30, 2025 | 27.36M |
| March 31, 2025 | 24.60M |
| December 31, 2024 | 29.30M |
| September 30, 2024 | 27.73M |
| June 30, 2024 | 29.25M |
| March 31, 2024 | 12.84M |
| December 31, 2023 | 15.35M |
| September 30, 2023 | 18.56M |
| June 30, 2023 | 18.59M |
| Date | Value |
|---|---|
| March 31, 2023 | 18.79M |
| December 31, 2022 | 16.87M |
| September 30, 2022 | 21.29M |
| June 30, 2022 | 28.92M |
| March 31, 2022 | 20.73M |
| December 31, 2021 | 22.00M |
| September 30, 2021 | 17.12M |
| June 30, 2021 | 14.03M |
| March 31, 2021 | 15.88M |
| December 31, 2020 | 9.336M |
| September 30, 2020 | 8.627M |
| June 30, 2020 | 7.345M |
| March 31, 2020 | 7.295M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 2.316B |
| Johnson & Johnson | 3.603B |
| Pfizer Inc. | 2.746B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |